Aim: The aim
of this study was to investigate the prevalence of metabolic syndrome according
to different metabolic syndrome definitions in children and adolescents with
congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
Material and Methods: A total number of 45 patients (31
patients with classical congenital adrenal hyperplasia due to 21-hydroxylase
deficiency and 14 patients with non-classical congenital adrenal hyperplasia)
were enrolled to the study. The anthropometric, clinical, hormonal findings and
the dose of hydrocortisone were analyzed starting from the initial day of
diagnosis until the beginning of our study and the metabolic controls
(good-bad) were evaluated in the follow-up period. At the last visit, systemic
and anthropometric examinations (involving measures of height, weight, waist
circumference and blood pressure) was performed by the same physician. Serum
lipid levels were examined and oral glucose tolerance tests were performed.
Metabolic syndrome prevalence in our patients was calculated with respect to
the modified criteria of WHO, IDF and NCEP ATP III.
Results: Metabolic syndrome was diagnosed in
only 1 (2.2%) of the 45 patients in the study according to modified WHO
definition, 8 patients (17.8%) received a diagnosis of metabolic syndrome
according to NCEP ATP III definition. Metabolic syndrome was diagnosed in 1
(3.3%) of 30 patients above 10 years of age according to IDF definition and 20%
of patients aged 6-10 years were considered to be risky for development of
metabolic syndrome. Conclusion: It
was found that the prevalence of metabolic syndrome was highest when NCEP ATP
III definition was used.
Amaç: Çalışmanın amacı 21
hidroksilaz eksikliğine bağlı konjenital adrenal hiperplazi tanısı olan çocuk
ve adolesanlarda farklı metabolik sendrom tanı kriterlerine göre metabolik
sendrom prevelansını belirlemektir.
Gereç ve Yöntemler: Çalışmaya konjenital adrenal hiperplazisi tanısı olan toplam 45 hasta (21
hidroksilaz eksikliğine bağlı klasik konjenital adrenal hiperplazi tanısı olan
31 hasta, non klasik konjenital adrenal hiperplazi tanısı alan 14 hasta) dahil
edildi. Hastaların antropometrik ölçümleri, klinik
değerlendirmeleri, hormonal sonuçları ve hidrokortizon dozu tanı anından
çalışmanın başladığı tarihe kadar incelendi ve izlemdeki metabolik durumları
(iyi-kötü) belirlenen kriterlere göre değerlendirildi. Son vizitte, hastaların
sistemik ve antropometrik değerlendirmeleri (boy,
kilo, bel çevresi ve kan basıncı ölçümlerini içeren) aynı tecrübeli klinisyen
tarafından yapıldı. Hastaların serum lipid düzeyleri ölçüldü ve hastalara oral
glukoz tolerans testi uygulandı. WHO, IDF ve NCEP ATP III modifiye kriterlerine göre metabolik sendrom prevalansı hesaplandı.
Bulgular: Çalışmamızda modifiye WHO kriterlerine göre yalnızca 1
(2,2%) hastada, NCEP ATP III kriterlerine göre ise 8 (17,8%) hastaya metabolik
sendrom tanısı konuldu. IDF kriterlerine göre 10 yaş üstü 30 hastadan 1’ine (3,3%) metabolik sendrom tanısı konulur
iken 6-10 yaş arası hastaların 20%’ sinin metabolik sendrom gelişimi
için risk altında olduğu saptandı.
Sonuç: Konjenital adrenal
hiperplazi tanılı çocuk ve adolesan hastalarda NCEP ATP III metabolik sendrom tanı kriterleri kullanıldığında en yüksek oranda
metabolik sendrom sıklığı saptanmıştır.
Primary Language | English |
---|---|
Subjects | Health Care Administration |
Journal Section | Orıgınal Artıcle |
Authors | |
Publication Date | September 30, 2018 |
Published in Issue | Year 2018 Volume: 9 Issue: 3 |
e-ISSN: 2149-8296
The content of this site is intended for health care professionals. All the published articles are distributed under the terms of
Creative Commons Attribution Licence,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.